CAC 40
7 957,57 +42,92 (+0,54 %) Euro Stoxx 50
4 921,48 +30,87 (+0,63 %) Dow Jones
38 675,68 +450,02 (+1,18 %) EUR/USD
1,0765 +0,0038 (+0,36 %) Gold future
2 310,10 +0,50 (+0,02 %) Bitcoin EUR
58 710,54 +3 636,95 (+6,60 %)
Daiichi Sankyo Company, Limited (D4S.F)
Daiichi Sankyo Company, Limited
3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo 103-8426
Japan
81 3 6225 1111
https://www.daiichisankyo.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein:
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Sunao Manabe D.V.M., Ph.D. | Group CEO & Executive Chairperson | 1,7M | S.O. | 1954 |
| Mr. Hiroyuki Okuzawa | President, COO & Representative Director | 669,76k | S.O. | 1962 |
| Mr. Masahiko Ohtsuki | Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director | 669,76k | S.O. | 1959 |
| Dr. Shoji Hirashima | Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director | 724,56k | S.O. | 1961 |
| Mr. Koji Ogawa | Managing Executive Officer, Head of Global Corporate Planning & Management and CFO | S.O. | S.O. | S.O. |
| Chiyu | General Manager of Finance & Accounting Department | S.O. | S.O. | S.O. |
| Hiroto Kashiwase | Managing Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQ | S.O. | S.O. | S.O. |
| Naoto Tsukaguchi | Gen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept. | S.O. | S.O. | S.O. |
| Kentaro Asakura | Vice President of Corporate Communications Department | S.O. | S.O. | S.O. |
| Ms. Marielle Cohard-Radice M.D. | Global Head of Development | S.O. | S.O. | S.O. |
Description
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Daiichi Sankyo Company, Limited en date du 1 mai 2024 est 1. Les scores principaux sont Audit : 1; Société : 1; Droits des actionnaires : 2; Compensation : 1.
